Skip to main
NTRA
NTRA logo

Natera (NTRA) Stock Forecast & Price Target

Natera (NTRA) Analyst Ratings

Based on 25 analyst ratings
Buy
Strong Buy 36%
Buy 60%
Hold 4%
Sell 0%
Strong Sell 0%

Bulls say

Natera Inc. has demonstrated significant financial growth, with revenue increasing nearly six-fold and gross margins improving by approximately 2000 basis points since 2019, establishing a strong foundation for future expansion. The expansion of Medicare Advantage reimbursement rates for the Signatera molecular residual disease test, now reaching mid-to-high 60% coverage, alongside a focus on higher priced tests, supports a positive growth trajectory and enhanced average selling prices. Furthermore, Natera's dominant positions in the non-invasive prenatal testing (NIPT) and minimal residual disease (MRD) markets position the company favorably within a combined $60 billion total addressable market, enhancing its ability to navigate regulatory challenges and capitalize on emerging opportunities in cancer screening.

Bears say

Natera Inc faces a significant risk of revenue decline if payors reduce or eliminate reimbursement for its diagnostic products, which could hamper its path to profitability. The company anticipates continued erosion in profit margins due to in-network pricing reductions as more commercial payors enter the market and the target addressable market expands to include average risk patients. Additionally, delays in clinical trials and external factors affecting diagnostic service delivery may further jeopardize Natera's long-term revenue growth strategy.

Natera (NTRA) has been analyzed by 25 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 60% recommend Buy, 4% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Natera (NTRA) Forecast

Analysts have given Natera (NTRA) a Buy based on their latest research and market trends.

According to 25 analysts, Natera (NTRA) has a Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $151.04, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $151.04, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Natera (NTRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.